Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SUPERx ACQUISITION OF BEGLEY WOULD DOUBLE TOTAL DRUGSTORES

Executive Summary

SUPERx ACQUISITION OF BEGLEY WOULD DOUBLE TOTAL DRUGSTORES of the Kroger spinoff to nearly 100 units and expand its operation into Kentucky. Phoenix, Ariz.-based SupeRx currently operates 51 stores, 27 in the Phoenix area, with the remainder located in Georgia and Alabama. In addition to its 43 drugstores, Begley operates seven institutional pharmacies, six home health centers and 127 dry cleaning outlets. On Jan. 20, SupeRx commenced a cash tender offer for all of Begley's common stock at $ 18.50 a share, a deal worth just over $ 12 mil. The proposal was the second for SupeRx in the same week. However, the Begley board is reportedly viewing the most recent SupeRx offer as inadequate. "On Jan. 18, SupeRx submitted a merger proposal to the Begley board to acquire all outstanding Begley shares for $ 18.50 per share," SupeRx stated in its Jan. 20 press release. "The Begley board has not as yet responded to SupeRx' proposal." According to a Securities & Exchange Commission 13-D filing, SuperRx has agreements to acquire 16.8%, or 111,835 shares, of Begley, including an agreement with Chairman Robert Begley's family to purchase all of their shares. SupeRx also disclosed a $ 15 mil. credit commitment from American Continental. The $ 18.50 per share represents a premium of nearly 50% above Begley's closing price of 12-1/2 at the end of 1987. The stock closed the week ended Jan. 29 at 17-1/2. The current SupeRx chain resulted from Kroger's "repositioning" of its 890-store Hook/SupeRx chain drug operation toward the end of 1986. Over 700 stores were taken private via a leveraged buyout by Kroger board member Philip Beekman and several executives. The remaining 180 stores were sold in separate deals, one of which included the sale of the Arizona, Georgia and Alabama stores to former Kroger drugstore exec Gerald Wolken, who now heads the private chain. For the third quarter ended Dec. 31, Begley reported flat sales of about $ 21 mil. and a precipitous 52% drop in net income, from $ 630,000 in the third quarter of fiscal 1987 to $ 300,000. Nine-month sales were up slightly, 3% to $ 58 mil., but net income plummeted 96%, from $ 650,000 to $ 30,000.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS013120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel